English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Parkinson’s disease (PD) is a neurodegenerative disorder with the loss of substantia nigra, pars compacts (SNc) neurons as its main pathology. Novel treatments for PD. include administration of non-immunosuppressant derivatives of neuroimmunophilin ligands (NILs), such as GPI-1046. Here, we investigate mRNA changes in the striatum of a 6 -hydroxydopamine (6 -OHDA) model of PD after treatment with GPI-1046, using National Institutes of Health (NIH) 15K mouse probes with two-colour DNA microarray hybridization. We compared the effects oflesioning, treatment and the interaction effects of lesioning and treatment using a 2 x 2 factorial microarray design. Significant changes were observed when comparing lesioning to GPI-1046 treatment but not with both lesioning and treatment. Quantitative polymerase chain reaction (QPCR) was used to confirm the direct interaction oflesioning and treatment versus no lesion and vehicle only treatment. A surprising result of the QPCR assay was a substantial increase in Presenilin 1 in the lesioned treated tissue in a majority of the animals tested. Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Functional genomic analysis of non-immunosuppressant neuroimmunophilin ligand in a rat Parkinson's model